In this guidance we highlight key points that should be considered by pharmacists in ensuring the safe supply of ellaOne® to patients.
Due to the nature of this medicine and the associated patient counselling requirements, a private consultation between the pharmacist and the individual patient is required. This consultation should take place in the pharmacy’s patient consultation area.
The products Summary of Product Characteristic (SmPC) and Package Leaflet are available to view on the HPRA website.